Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Vanderbilt University University of California, San Francisco |
---|---|
Information provided by: | Vanderbilt University |
ClinicalTrials.gov Identifier: | NCT00698399 |
This is an observational study examining serum markers in patients who are undergoing either a cadaveric liver transplant or a living related liver transplant.
Condition |
---|
Liver Transplant |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Serum Markers of Ischemia Reperfusion Injury in Liver Transplant Patients, Phase II |
serum of patients who are undergoing liver transplantation surgery
Enrollment: | 40 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
Live Donor
|
2
Cadaveric Donor
|
The Departments of Anesthesiology are conducting an observational trial of markers in the serum of patients who are undergoing liver transplantation surgery. This study will utilize the biological markers, trimethylamine-N-oxide (TMAO), NGAL, and cystatin-C, sensitive markers of renal medullary injury in the blood and allantoin, a marker of oxidative stress as indicators of renal injury in a kidney during liver transplants. It is hypothesized that: (1) these markers are less pronounced in living donor liver transplant recipient patients than in cadaveric liver transplant recipients, and (2) these markers are less pronounced in cadaveric liver transplant recipients in which a "piggy-back" technique was used versus recipients in which a total venous occlusion technique was used. This study will be done in a multi-center format, along with researchers at UCSF
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Subjects will be recruited from those on the list awaiting liver transplantation at Vanderbilt University Medical Center (VUMC). They will be recruited by the investigators prior to the time of their transplantation surgery
Inclusion Criteria:
Exclusion Criteria:
United States, Tennessee | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States, 37212 |
Principal Investigator: | Jeffrey M Waldman, M.D. | Vanderbilt University |
Responsible Party: | Vanderbilt University Medical Center ( Jeffrey Michael Waldman, M.D. ) |
Study ID Numbers: | 80237 |
Study First Received: | June 12, 2008 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00698399 History of Changes |
Health Authority: | United States: Institutional Review Board |
liver transplant TMAO NGAL cystatin-C |
Ischemia Reperfusion Injury Liver Transplant LTx allantion |
Postoperative Complications Vascular Diseases Ischemia Cystatins Reperfusion Injury |
Pathologic Processes Postoperative Complications Vascular Diseases |
Cardiovascular Diseases Ischemia Reperfusion Injury |